Agenus Q3 2026 net income drops 96% year over year to $2.8 million
- Agenus’ third-quarter 2026 net income fell 96% year over year to $2.8 million; revenue rose to $31.5 million.
- Cash, cash equivalents and short-term investments increased from the previous quarter to $86.9 million at September 30, 2026.
- Armenia granted the first worldwide marketing authorizations for botensilimab and balstilimab, each for use in combination with the other.
- The Phase 3 ROBBIN trial remains on track for first patient enrollment in Q1 2027.
- July financing proceeds are expected to support operations through Q3 2027, extending through year-end 2031 if milestone-aligned warrants are fully exercised.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050730BIZWIRE_USPR_____20261105_BW453521) on November 05, 2026, and is solely responsible for the information contained therein.